PETAL Trial: Impact of Gallium-68 Pentixafor PET-CT on Surgical Outcomes in Primary Aldosteronism
Launched by SEOUL NATIONAL UNIVERSITY HOSPITAL · Jun 16, 2025
Trial Information
Current as of June 26, 2025
Recruiting
Keywords
ClinConnect Summary
This clinical trial is studying a new imaging test called Gallium-68 Pentixafor PET/CT to see if it can help doctors better plan surgery for people with primary aldosteronism, a condition where the adrenal glands make too much of a hormone called aldosterone. This hormone imbalance can cause high blood pressure. The study wants to find out if adding this new scan to the usual tests improves the success of surgery that removes the affected adrenal gland.
People who are 19 years or older and have been diagnosed with primary aldosteronism following standard guidelines may be eligible to join. Participants must have already had a regular adrenal gland CT scan and be willing to have surgery. Pregnant or breastfeeding women and those who cannot or do not want to have certain scans or surgery won’t be able to join. If you participate, you will have the new imaging scan in addition to the usual tests, and your doctors will use this information to decide on the best treatment. This study is currently looking for volunteers and includes adults of all genders.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Age ≥19 years
- • Diagnosed with PA per 2016 Endocrine Society guidelines
- • Underwent adrenal CT
- • Signed informed consent
- Exclusion Criteria:
- • Women who are pregnant, breastfeeding, or may become pregnant
- • Individuals who refuse to undergo surgery
- • Individuals for whom 68Ga-Pentixafor PET/CT, 11C-Metomidate PET/CT, or adrenal venous sampling (AVS) is not feasible or is refused due to underlying conditions
- • Individuals who refuse or experience adverse effects from dexamethasone premedication required for 11C-Metomidate PET/CT
- • Individuals with a history of abdominal open surgery or retroperitoneal surgery on the same side as the planned adrenalectomy
- • Any individual deemed unsuitable for the study at the discretion of the investigator
About Seoul National University Hospital
Seoul National University Hospital (SNUH) is a leading medical institution in South Korea, renowned for its commitment to advancing healthcare through innovative research and clinical excellence. As a prominent clinical trial sponsor, SNUH integrates cutting-edge scientific inquiry with patient-centered care, facilitating the development of novel therapies and treatment protocols. The hospital boasts a diverse range of specialized departments and a robust infrastructure for conducting clinical studies, ensuring rigorous adherence to ethical standards and regulatory compliance. By fostering collaboration among multidisciplinary teams, SNUH aims to contribute significantly to global medical advancements and improve patient outcomes.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Seoul, , Korea, Republic Of
Seoul, Jongno Gu, Korea, Republic Of
Patients applied
Trial Officials
Su-jin Kim, M.D, Ph.D
Principal Investigator
Seoul National University Hospital
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported